



04-15-04

Certificate of Mailing by Express Mail

Express Mail Label No.: EV 312852556 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 and is addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

By: Barbara Bryant  
Barbara Bryant

Date: April 14, 2004

Patent  
Attorney's Docket No. P-142-US1  
Customer No. 27038

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
MAMMEN et al.	)	Group Art Unit: 1614
	)	
Application No.: 10/696,464	)	Examiner: Not yet assigned
	)	
Filed: October 29, 2003	)	
	)	
For: SUBSTITUTED 4-AMINO-1-	)	
(PYRIDYLMETHYL)PIPERIDINE	)	
AND RELATED COMPOUNDS	)	

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 CFR §1.56, Applicants hereby submit the following information in conformance with CFR §§1.97 and 1.98. Enclosed herewith is a PTO/SB/08a form that lists the documents being submitted for consideration by the Examiner. Copies of the cited documents are also enclosed herewith, except as noted below.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Copies of cited U.S. patents and published patent applications are not being provided with this Information Disclosure Statement, since the USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit such documents for U.S. national patent applications filed after June 30, 2003 (see 1276 *Off. Gaz. Pat. Off.* 55, Aug. 5, 2003). Copies of all other cited documents are enclosed herewith.

Pursuant to 37 C.F.R. §1.98(a)(3)(i), a concise explanation of the relevance of the following non-English language document is provided:

(1) CH 628 885 (in French language listed as B7 on the accompanying Form PTO/SB/08a) discloses various piperidine derivatives.

Consideration of the listed documents is respectfully requested. Additionally, the Examiner is respectfully requested to return an initialed copy of the enclosed PTO/SB/08a form to Applicants with the next official action in this application.


This Information Disclosure Statement is being filed before the mailing date of a first official action on the merits for this application and therefore, no fee or certification is required under 37 CFR §1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees under 37 CFR §1.97(c) for submission of this paper to Deposit Account No. 50-0344.

Should there be any questions concerning the cited documents, the Examiner is encouraged to telephone the undersigned attorney for Applicants at (650) 808-6406 (direct).


Respectfully submitted,

THERAVANCE, INC.

Date: 4/14/04

By:   
Jeffrey A. Hagenah, Ph. D.  
Registration No. 35,175

THERAVANCE, INC.  
901 Gateway Boulevard  
South San Francisco, CA 94080  
Tel: (650) 808-6000  
Fax: (650) 808-6078



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Use this form for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	10/696,464
Filing Date	October 29, 2003
First Named Inventor	Mathai MAMMEN
Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	P-142-US1

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	A1	US- 3,192,206	06-29-1965	Lunsford et al.	
	A2	US- 3,192,210	06-29-1965	Lunsford et al.	
	A3	US- 3,192,221	06-29-1965	Lunsford et al.	
	A4	US- 3,984,557	10-05-1976	Welstead, Jr.	
	A5	US- 4,002,766	01-11-1977	Welstead, Jr.	
	A6	US- 4,594,343	06-10-1986	Shanklin, Jr. et al.	
	A7	US- 4,810,713	03-07-1989	Yanni et al.	
	A8	US- 4,950,674	08-21-1990	Yanni et al.	
	A9	US- 5,026,858	06-25-1991	Vega-Noverola et al.	
	A10	US- 5,028,616	07-02-1991	Desai et al.	
	A11	US- 5,070,087	12-03-1991	Teng et al.	
	A12	US- 5,096,890	03-17-1992	Cross et al.	
	A13	US- 5,233,053	08-03-1993	Cross et al.	
	A14	US- 5,281,601	01-25-1994	Cross et al.	
	A15	US- 5,340,831	08-23-1994	Cross et al.	
	A16	US- 5,344,835	09-06-1994	Alker et al.	
	A17	US- 5,486,527	01-23-1996	Alker et al.	
	A18	US- 5,607,950	03-04-1997	Alker et al.	
	A19	US- 5,750,540	05-12-1998	Tsuchiya et al.	
	A20	US- 5,932,594	08-03-1999	Cross et al.	
	A21	US- 6,130,232	10-10-2000	Mase et al.	
	A22	US- 6,319,920 B1	11-20-2001	Caroon et al.	
	A23	US- 2003/0055080 A1	03-20-2003	Fomer et al.	


### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B1	WO 91/09013 A1	06-27-1991	Pfizer Limited		
	B2	WO 99/43657 A1	09-02-1999	F. Hoffmann-La Roche AG		
	B3	WO 01/04118 A2	01-18-2001	Almirall Prodesfarma S. A.		
	B4	WO 02/051841 A1	07-04-2002	Almirall Prodesfarma, S. A.		
	B5	WO 02/053564 A2	07-11-2002	Almirall Prodesfarma AG		
	B6	WO 03/048124 A1	06-12-2003	F. Hoffmann-La Roche AG		
	B7	CH 628 885 A5 (in French language)	03-31-1982	Anphar S. A.		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/696,464
Filing Date	October 29, 2003
First Named Inventor	Mathai MAMMEN
Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	P-142-US1

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B8	EP 0 178 946 A2	04-23-1986	A. H. Robins Company, Inc.		
	B9	EP 0 178 947 A2	04-23-1986	A. H. Robins Company, Inc.		
	B10	EP 0 235 463 A2	09-09-1987	A. H. Robins Company, Inc.		
	B11	EP 0 388 054 B1	09-19-1990	Pfizer Limited		
	B12	EP 0 863 141 A1	09-09-1998	Banyu Pharmaceutical Co., Ltd.		
	B13	EP 0 930 298 A1	07-21-1999	Banyu Pharmaceutical Co., Ltd.		
	B14	EP 0 999 205 A1	05-10-2000	Mitsubishi-Tokyo Pharmaceuticals, Inc.		
	B15	EP 1 020 449 A1	07-19-2000	Mitsubishi-Tokyo Pharmaceuticals, Inc.		
	B16	GB 1 507 462	04-12-1978	Antonio Gallardo, S. A.		
	B17	GB 1 575 310	09-17-1980	Anphan S. A.		
	B18	GB 1 593 851	07-22-1981	Antonio Gallardo S. A.		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	BROADLEY et al., "Muscarinic Receptor Agonists and Antagonists", Molecules 2001, 6, pp 142-193 (2001)	
	C2	EGLIN et al., "Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential", DN&P, 10(8), pp 462-469 (1997)	
	C3	EGLIN et al., "Selective modulation of muscarinic receptor subtypes: therapeutic potential", Emerging Drugs: The Prospect for Improved Medicines/Annual Executive Briefing 1998; pp 67-79 (1998)	
	C4	GRAUL et al., "Darifenacin", Drugs of the Future 1996, 21 (11); pp 1105-1108 (1996)	
	C5	MORAGUES et al., "Dopaminergic Activity in a Series of N-Substituted 2-Aminopyrimidines", Il Farmaco -Ed. Sc. -Vol. 35 - Fasc. 11; pp 951-964 (1980)	
	C6	SHUM et al., "The Design and Synthesis of Purine Inhibitors of CDK2.III", Nucleosides, Nucleotides & Nucleic Acids, 20(4-7), pp 1067-1078 (2001)	
	C7	ZLOTOS et al., "Muscarinic receptor agonists and antagonists", Exp. Opin. on Ther. Patents, 9(8), pp1029-1053 (1999)	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.